Skip to content
AnalystLens

MRK · Merck

41 filings

10-K

MRK 10-K Annual Reports

Merck - 41 annual reports

Filing record · 2016–202610-K1210-Q338-K88

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 88 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25
  1. 2025

    Merck Annual Report, Year Ended Dec 31, 2025

    Merck & Co., Inc. reported total sales of $65.0 billion for the fiscal year 2025, a modest 1% increase year-over-year (2% excluding foreign exchange impact). This growth was primarily driven by strong performance in the oncology franchise, particularly Keytruda, and the Animal Health segment, alongside contributions from the cardiometabolic and respiratory portfolio, including the launch of Winrevair, and the acquisition of Verona Pharma which added Ohtuvayre. However, the company faced headwinds in its vaccines segment, notably a significant decline in Gardasil/Gardasil 9 sales in China due to inventory issues and local competition, as well as lower sales in the immunology and virology segments. Merck continued to bolster its pipeline through strategic business development, including the acquisition of Cidara Therapeutics and Verona Pharma, and exclusive license agreements for promising early-stage candidates. The company also advanced its late-stage pipeline with numerous regulatory submissions and positive Phase 3 trial results across various therapeutic areas. Despite revenue growth, the company announced a significant restructuring program aimed at optimizing operations and supporting future growth, expected to result in annual cost savings. Investors should monitor upcoming patent expirations for key products like Januvia and Janumet, and the ongoing impact of regulatory changes and pricing pressures, particularly from the Inflation Reduction Act, which is expected to affect Keytruda's U.S. sales in the future.

    Feb 24, 2026
  2. 2024

    Merck Annual Report, Year Ended Dec 31, 2024

    Merck & Co., Inc. (MRK) reported robust sales growth of 7% to $64.2 billion in 2024, driven primarily by strong performance in oncology, cardiovascular, and animal health sectors. The company's flagship oncology drug, Keytruda, saw a significant 18% increase in global sales, reaching $29.5 billion and demonstrating continued strong demand across numerous indications and earlier-stage cancer treatments. The animal health segment also contributed positively with a 4% sales increase. Despite overall growth, the company experienced a decline in its diabetes franchise due to competitive pressures and Januvia/Janumet patent expirations, as well as reduced sales of Lagevrio (COVID-19 medication) and a notable dip in Gardasil/Gardasil 9 sales in China, a trend expected to continue into 2025. Merck actively pursued strategic business development, including several key acquisitions and licensing agreements in the ophthalmology, immunotherapy, and oncology spaces, bolstering its pipeline. The company also advanced its regulatory submissions and secured numerous product approvals globally throughout 2024, highlighting its ongoing commitment to innovation and addressing unmet medical needs. Looking ahead, Merck faces potential headwinds from pricing pressures and government regulations, notably the Inflation Reduction Act (IRA), which is expected to impact Keytruda's U.S. sales in the future. However, the company's diversified portfolio, strong pipeline, and strategic business development initiatives position it for continued growth. Investors should monitor developments in Keytruda's market exclusivity, the impact of the IRA on pricing, and the success of new product launches and pipeline advancements, particularly in oncology and cardiovascular diseases.

    Feb 25, 2025
  3. 2023-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 2023

    This filing is an amendment (10-K/A) to Merck & Co., Inc.'s annual report for the period ending December 30, 2023, filed on April 10, 2024. As this is a Part III and Part IV filing, it primarily incorporates by reference information from Merck's Proxy Statement for the May 28, 2024, Annual Shareholder Meeting and previously filed 10-K reports. Key information regarding directors, executive officers, corporate governance, and executive compensation is detailed within the referenced proxy statement, emphasizing adherence to a Code of Conduct and ethical business practices. Furthermore, the filing includes details on equity compensation plans, outlining the number of securities available for issuance and outstanding options as of December 31, 2023. It also lists various exhibits, including incorporation by reference of key corporate documents, indentures, and executive compensation plans, along with the necessary certifications from the CEO and CFO. Investors should refer to the referenced Proxy Statement for comprehensive details on governance and compensation practices.

    Apr 11, 2024
  4. 2023

    Merck Annual Report, Year Ended Dec 31, 2023

    Merck & Co., Inc. reported total sales of $60.1 billion for the fiscal year ended December 30, 2023, representing a 1% increase year-over-year (4% excluding foreign exchange impacts). This growth was primarily driven by strong performance in the oncology franchise, led by Keytruda, and the vaccines franchise, notably Gardasil/Gardasil 9. The company also saw increased alliance revenue from Lynparza and Lenvima, along with growth in hospital acute care and animal health products. However, these gains were partially offset by declines in the virology franchise, mainly due to lower sales of Lagevrio, and decreased sales in the diabetes segment from Januvia/Janumet. Merck continued to strengthen its pipeline and market position through strategic business development, including significant acquisitions such as Prometheus Biosciences and Imago BioSciences, and collaborations like the one with Daiichi Sankyo for antibody-drug conjugates. The company advanced numerous late-stage pipeline candidates and secured over 25 regulatory approvals in major markets during the year, highlighting continued innovation and expansion of its therapeutic offerings. Despite ongoing pricing pressures and global economic challenges, Merck remains focused on driving growth through its core therapeutic areas and expanding its reach in diverse markets.

    Feb 26, 2024
  5. 2022

    Merck Annual Report, Year Ended Dec 31, 2022

    Merck & Co., Inc. reported robust performance in 2022, with total sales reaching $59.3 billion, a 22% increase year-over-year, driven significantly by its oncology franchise, particularly Keytruda, and strong sales from Lagevrio (a COVID-19 treatment). The company continues to focus on strategic business development, announcing several collaborations and acquisitions to bolster its pipeline in key therapeutic areas like oncology and infectious diseases. While sales growth was strong, investors should note the expected significant decline in Lagevrio sales for 2023, as the COVID-19 pandemic's impact wanes. Merck also highlighted its commitment to returning value to shareholders through dividends and share repurchases, alongside ongoing investments in research and development to drive future growth. Key risks and challenges identified include the ongoing pricing pressures in the healthcare industry, competition from generic products, and potential impacts from global economic conditions and regulatory changes, such as the Inflation Reduction Act. The company's patent portfolio remains crucial, with ongoing efforts to defend intellectual property rights against challenges.

    Feb 24, 2023
  6. 2021

    Merck Annual Report, Year Ended Dec 31, 2021

    Merck & Co., Inc. (MRK) reported strong financial performance for the fiscal year ended December 31, 2021, with total sales reaching $48.7 billion, a 17% increase year-over-year, driven primarily by growth in its oncology franchise, particularly Keytruda, and its vaccines business. The company also saw significant contributions from its Animal Health segment and the newly authorized COVID-19 antiviral treatment, molnupiravir. Merck successfully completed strategic acquisitions, including Acceleron Pharma and Pandion Therapeutics, to bolster its pipeline and expand its therapeutic reach in areas like pulmonary diseases and autoimmune disorders. Furthermore, Merck continued to advance its broad pipeline, achieving notable regulatory milestones and receiving over 30 approvals across key markets. The company also completed the spin-off of its Organon business, streamlining its portfolio and allowing for a more focused approach on its core growth drivers. Despite some headwinds from COVID-19 related disruptions, which impacted physician-administered products, Merck demonstrated resilience and a robust commercial execution, positioning itself for continued growth in the pharmaceutical and animal health sectors.

    Feb 25, 2022
  7. 2020

    Merck Annual Report, Year Ended Dec 31, 2020

    Merck & Co., Inc. reported total sales of $47.994 billion for the fiscal year ending December 30, 2020, representing a 2% increase over the previous year, or 4% excluding foreign exchange impacts. This growth was primarily driven by strong performance in the oncology franchise, particularly with Keytruda, and increased sales in certain hospital acute care products and the animal health division. Despite facing headwinds from the COVID-19 pandemic, which negatively impacted sales of physician-administered products by an estimated $2.5 billion, Merck demonstrated resilience. The company advanced its strategic priorities, including completing significant business development transactions and investing in its pipeline. A key strategic move was the announcement of the planned spin-off of its Women's Health, Biosimilars, and Established Brands businesses into a new entity, Organon & Co., expected in the latter half of 2021. This spin-off aims to create two focused companies, allowing each to better pursue its respective market opportunities and strategies.

    Feb 25, 2021
  8. 2019

    Merck Annual Report, Year Ended Dec 31, 2019

    Merck & Co., Inc.'s 2019 10-K filing reveals a strong financial performance driven primarily by its Pharmaceutical segment, with notable growth in Keytruda, vaccines like Gardasil/Gardasil 9, and hospital acute care products such as Bridion. Total sales reached $46.8 billion, an increase of 11% year-over-year, demonstrating the company's robust market position and the effectiveness of its key growth drivers. The company continues to invest heavily in research and development, with significant progress in its oncology pipeline and regulatory approvals for Keytruda across various cancer types and geographies. Merck also announced plans to spin off its women's health, legacy brands, and biosimilars businesses into a new, independent company to better focus on its core strengths. This strategic move aims to unlock further value and enhance agility in a dynamic healthcare landscape. The Animal Health segment also showed steady growth, contributing positively to the overall results. Despite overall strong performance, Merck faces ongoing challenges from generic competition, pricing pressures globally, and evolving healthcare regulations. The company's patent portfolio remains critical, with key products like Januvia and Janumet facing upcoming patent expirations, necessitating continued innovation and pipeline development to offset potential sales declines. The company's financial health remains strong, supported by significant cash flows from operations and a commitment to returning capital to shareholders through dividends and share repurchases.

    Feb 26, 2020
  9. 2018

    Merck Annual Report, Year Ended Dec 31, 2018

    Merck & Co., Inc. reported solid financial performance for the fiscal year ending December 30, 2018, with total sales reaching $42.3 billion, a 5% increase over the previous year. This growth was primarily driven by strong sales in the oncology segment, notably from Keytruda, and robust performance in vaccines, particularly Gardasil/Gardasil 9. The Animal Health division also contributed positively to the overall revenue increase. The company demonstrated a commitment to innovation through continued investment in its research and development pipeline, focusing on key areas like immuno-oncology. Merck also actively pursued business development opportunities, including strategic collaborations and acquisitions, to enhance its portfolio and future growth prospects. The company returned significant capital to shareholders through dividends and share repurchases, reflecting its financial strength and confidence in its strategic direction. Despite facing ongoing pricing pressures and generic competition in certain product lines, Merck's diversified business segments and strong product pipeline position it for continued success.

    Feb 27, 2019
  10. 2017

    Merck Annual Report, Year Ended Dec 31, 2017

    Merck & Co., Inc. reported total sales of $40.122 billion for the fiscal year ending December 30, 2017. The Pharmaceutical segment remains the primary revenue driver, with significant contributions from Keytruda, Januvia/Janumet, and Gardasil/Gardasil 9. However, the company experienced sales declines in established products like Zetia/Vytorin and Remicade due to generic and biosimilar competition. The company also faced challenges from a cyber-attack in June 2017, which impacted sales and incurred additional expenses, and a hurricane that affected operations in Puerto Rico. Despite these headwinds, Merck continued to invest heavily in research and development, with significant progress noted in expanding Keytruda's indications and advancing its pipeline for HIV and diabetes. Merck's financial performance in 2017 was impacted by a provisional net tax charge related to the enactment of the U.S. Tax Cuts and Jobs Act, as well as charges related to collaborations. The company actively returned capital to shareholders through dividends and share repurchases, signaling confidence in its ongoing operations and future growth prospects. Investors should monitor the impact of ongoing patent expirations and the success of new product launches and pipeline developments, particularly in the oncology and infectious disease areas.

    Feb 27, 2018
  11. 2016

    Merck Annual Report, Year Ended Dec 31, 2016

    Merck & Co., Inc. reported total sales of $39.8 billion for the fiscal year ended December 30, 2016, a slight increase of 1% from the prior year, impacted by a 2% unfavorable foreign exchange effect. The Pharmaceutical segment remains the sole reportable segment, accounting for the vast majority of revenue. Key growth drivers included the oncology franchise, particularly Keytruda, alongside strong performance in Hepatitis C treatments (Zepatier) and vaccines. However, these gains were partially offset by declines in established products like Remicade and Nasonex due to generic and biosimilar competition. The company made significant investments in research and development, totaling $10.1 billion, reflecting its commitment to innovation and pipeline expansion. Merck also demonstrated a commitment to shareholder returns, raising its quarterly dividend and repurchasing shares. The company experienced significant IPR&D impairment charges in 2016, notably related to the uprifosbuvir program for HCV, highlighting the inherent risks in drug development. Legal settlements, including a substantial charge for Keytruda patent litigation, impacted the financial results. Overall, the company navigated a complex operating environment marked by pricing pressures and regulatory scrutiny, while strategically advancing its product portfolio and R&D pipeline.

    Feb 28, 2017
  12. 2015

    Merck Annual Report, Year Ended Dec 31, 2015

    Merck & Co., Inc. reported total sales of $39.5 billion for the fiscal year ended December 30, 2015, representing a 6% decrease compared to the prior year, partly due to unfavorable foreign exchange rates and the divestiture of its Consumer Care segment. Despite the overall sales decline, the company experienced volume growth in key areas such as oncology (driven by Keytruda), diabetes, and vaccines, along with a positive performance in its Animal Health business. Significant product approvals and expanded indications in 2015 included Keytruda for advanced melanoma and metastatic non-small-cell lung cancer, and Bridion for surgical reversal of neuromuscular blockade. The company also advanced its pipeline with several drug candidates under regulatory review and in Phase 3 development, highlighting a strategic focus on innovation in critical therapeutic areas like cancer and diabetes. Merck continued its commitment to returning capital to shareholders, with $9.3 billion returned through dividends and share repurchases in 2015. The company is actively managing its cost structure through ongoing restructuring programs, which were substantially completed by the end of 2015, contributing to projected annual net cost savings. Management emphasizes a R&D-focused strategy, augmented by business development activities such as strategic acquisitions and collaborations, to enhance its product pipeline and address unmet medical needs.

    Feb 26, 2016
  13. 2014

    Merck Annual Report, Year Ended Dec 31, 2014

    Merck & Co., Inc.'s 2014 10-K filing reveals a year of strategic transformation, marked by a 4% decline in sales to $42.2 billion, largely attributed to product divestitures, including the significant sale of its Consumer Care segment, and the loss of market exclusivity for several key products. Despite the revenue dip, the company achieved several important product approvals, including Keytruda for advanced melanoma and Gardasil 9 for HPV prevention, signaling a strong focus on innovation and future growth drivers. The company also made significant pipeline advancements and strategic acquisitions, notably the acquisition of Cubist Pharmaceuticals to bolster its infectious disease portfolio. Restructuring efforts are progressing well, aiming for substantial cost savings by the end of 2015. Management remains focused on prioritizing R&D and commercial resources toward areas with high unmet medical needs and significant growth potential, demonstrating a commitment to long-term value creation despite near-term revenue headwinds from divestitures and patent expirations.

    Feb 27, 2015
  14. 2013

    Merck Annual Report, Year Ended Dec 31, 2013

    Merck & Co., Inc. reported total sales of $44.03 billion for the fiscal year ended December 30, 2013. This represents a 7% decrease from the previous year, largely attributed to the loss of market exclusivity for key products like Singulair, coupled with ongoing global healthcare cost containment pressures. Despite the revenue decline, Merck demonstrated effective cost management, with marketing and administrative expenses and R&D costs decreasing by over $1.5 billion combined compared to 2012. The company also highlighted a significant restructuring program initiated in October 2013, aiming to reduce its workforce by approximately 8,500 positions and sharpen its commercial and R&D focus to drive future growth. Merck continued to return value to shareholders, repurchasing shares and paying dividends, signaling confidence in its long-term strategy and pipeline.

    Feb 27, 2014
  15. 2012

    Merck Annual Report, Year Ended Dec 31, 2012

    Merck & Co., Inc. reported $47.3 billion in worldwide sales for 2012, a slight 2% decrease from 2011, impacted by the U.S. patent expiration of Singulair. Despite this, the company demonstrated resilience with a 1% sales increase excluding foreign exchange impacts, driven by growth in key products like Januvia, Janumet, Gardasil, and Victrelis. Merck continued to focus on cost management, reducing operating expenses, and advancing its robust research and development pipeline, with several key drug candidates under regulatory review and in late-stage development. The company also highlighted strategic growth initiatives, including geographic expansion into high-growth markets, expansion into complementary Animal Health and Consumer Care businesses, and continued investment in innovation. Despite facing pricing pressures globally and the ongoing impact of healthcare reform, Merck demonstrated strong operational execution and maintained its commitment to returning capital to shareholders through dividends and share repurchases. The company also addressed significant legal settlements, notably the ENHANCE litigation, which impacted 2012 earnings but was covered by insurance recoveries.

    Feb 28, 2013
  16. 2011

    Merck Annual Report, Year Ended Dec 31, 2011

    Merck & Co., Inc. reported strong sales growth of 4% to $48.0 billion for the fiscal year ended December 31, 2011, driven by key products like Januvia, Janumet, and Singulair, along with contributions from their Animal Health division and the launch of Victrelis. The company continued its strategic focus on accelerating revenue growth and cost efficiencies through its Merger Restructuring Program, which is on track to deliver substantial savings. Despite facing patent expirations for some products and the ongoing impact of healthcare reforms and European austerity measures, Merck demonstrated resilience. The company also advanced its research and development pipeline, with several new drug candidates under regulatory review and in late-stage development, signaling a commitment to future growth.

    Feb 28, 2012
  17. 2010

    Merck Annual Report, Year Ended Dec 31, 2010

    Merck & Co., Inc. (MRK) reported a significant increase in sales to $46.0 billion for the fiscal year ended December 31, 2010. This growth was primarily driven by the full-year inclusion of results from the Schering-Plough merger completed in November 2009, which integrated legacy Schering-Plough products like Remicade and Nasonex, as well as Zetia and Vytorin. The company experienced challenges including patent expirations for key products such as Cozaar/Hyzaar, leading to sales declines in those areas. Additionally, Merck incurred substantial restructuring costs totaling $1.8 billion related to the integration of Schering-Plough, aiming for significant future cost savings. The company also faced increased expenses due to U.S. healthcare reform legislation and global austerity measures impacting pricing. Merck's pipeline shows progress with new approvals like Dulera and updated indications for Gardasil. However, the company also recorded a significant impairment charge of $1.7 billion related to the vorapaxar development program. Investors should note the ongoing arbitration with Centocor regarding Remicade and Simponi rights, which could materially affect future results.

    Feb 28, 2011
  18. 2009

    Merck Annual Report, Year Ended Dec 31, 2009

    Merck & Co., Inc. (MRK) completed a significant merger with Schering-Plough Corporation in November 2009, creating a larger, more diversified pharmaceutical entity. This merger is the defining event for the 2009 fiscal year, impacting the company's operational structure, financial results, and strategic outlook. The combined company benefits from an expanded product portfolio and research and development pipeline, aiming for significant cost synergies and enhanced market presence. Financially, the merger and the sale of the Merial animal health business contributed significantly to the company's results in 2009, including substantial one-time gains. While the company faced challenges such as patent expirations for key products like Cozaar and Hyzaar, the strategic integration and pipeline development signal a focus on long-term growth and a strengthened market position.

    Mar 1, 2010
  19. 2008

    Merck Annual Report, Year Ended Dec 31, 2008

    This 10-K, filed February 27, 2009, is from Schering-Plough Corporation (NYSE: SGP), not Merck & Co. (MRK). Schering-Plough and Merck operate the cholesterol franchise (VYTORIN and ZETIA) through an equity-method joint venture, so those products' sales are not in Schering-Plough's reported net sales. The filing covers fiscal 2008, a year of transformation. Net sales rose 46% to $18.5 billion, driven largely by the November 2007 acquisition of Organon BioSciences (OBS), which contributed $5.4 billion. Net income available to common shareholders was $1.75 billion, or $1.07 per diluted share, helped by a $160 million gain on divested Animal Health products and $1.9 billion of equity income from the cholesterol joint venture. Operating cash flow was $3.4 billion, and net debt fell to $4.8 billion from $7.1 billion. The main investor concern is the cholesterol franchise. Global VYTORIN and ZETIA sales fell 11% in 2008, and U.S. sales fell 24%, after the ENHANCE trial results (January 2008) and the SEAS trial (July 2008) drew heavy media attention, congressional and state investigations, and securities and consumer class actions. Management expects 2009 U.S. cholesterol sales to be lower than 2008, while international sales should keep growing. Management also reported a Productivity Transformation Program targeting $1.5 billion of annualized savings by 2012, with about $1.25 billion by end-2010, and R&D spending of $3.5 billion, which it expects to grow in the mid-single digits in 2009. Growth now rests on a broader base: REMICADE (international sales of $2.1 billion, up 28%), TEMODAR, NASONEX, and the newly acquired women's health and central nervous system products. Offsetting risks include loss of exclusivity for several products, competitive and pricing pressure in the U.S., and an expanding litigation and regulatory agenda. Schering-Plough's Moody's, S&P and Fitch ratings are investment grade (Baa1, A-, BBB+), with outlooks revised to stable.

    Feb 27, 2009
  20. 2007-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 2007

    Schering-Plough reported consolidated net sales of $12.7 billion for the year ended December 31, 2007, a 20% increase over the prior year, largely driven by the acquisition of Organon BioSciences N.V. (OBS) and growth in key pharmaceutical products like REMICADE, TEMODAR, and NASONEX. However, the company incurred a net loss of $1.6 billion, primarily due to significant purchase accounting charges, including $3.8 billion for acquired in-process research and development related to the OBS acquisition. The company's cholesterol franchise, managed through a joint venture with Merck, continued to show strong sales growth in 2007, though early 2008 saw negative media scrutiny and prescription declines for VYTORIN and ZETIA following the release of ENHANCE clinical trial results, leading to investigations and litigation. Schering-Plough's R&D spending increased significantly, reflecting investments in its pipeline and the OBS acquisition, with continued expected increases to support late-stage development. Investors should note the substantial impact of the OBS acquisition on both sales and reported losses, the ongoing legal and regulatory scrutiny surrounding the cholesterol joint venture products, and the company's reliance on key products like REMICADE and the joint venture products for future profitability. The company's financial position was strengthened by significant debt and equity issuance to finance the OBS acquisition. Despite the net loss in 2007, operating cash flow remained positive.

    Mar 3, 2008
  21. 2007

    Merck Annual Report, Year Ended Dec 31, 2007

    Schering-Plough reported consolidated net sales of $12.7 billion for the fiscal year ending December 30, 2007, a 20% increase from the prior year, largely driven by the transformative acquisition of Organon BioSciences N.V. (OBS) in November 2007 and strong performance in its Human Prescription Pharmaceuticals segment. However, the company posted a net loss of $1.6 billion for the year, primarily due to significant purchase accounting charges related to the OBS acquisition, including a $3.8 billion charge for acquired in-process research and development. Despite the net loss, the company generated $2.6 billion in cash flow from operating activities. Key product sales, including REMICADE, NASONEX, and TEMODAR, demonstrated robust growth, contributing to the overall increase in revenue. The company also highlighted ongoing research and development investments, with spending increasing by 34% to $2.9 billion, signaling a commitment to pipeline development. Investors should note the significant impact of the OBS acquisition on the company's balance sheet and the ongoing integration process. Additionally, the company disclosed potential risks related to its Merck/Schering-Plough cholesterol joint venture products, VYTORIN and ZETIA, due to media scrutiny surrounding the ENHANCE clinical trial, which had begun impacting prescriptions in early 2008.

    Feb 29, 2008
  22. 2006

    Merck Annual Report, Year Ended Dec 31, 2006

    Schering-Plough Corporation's 10-K for fiscal 2006 reports net sales of $10.6 billion, up 11 percent from $9.5 billion in 2005, with net income available to common shareholders of $1.1 billion ($1.057 billion), compared with $183 million in 2005. Diluted EPS was $0.71 versus $0.12. Results were significantly supported by equity income from the Merck/Schering-Plough cholesterol joint venture, which rose to $1.459 billion from $873 million, reflecting growing global sales of VYTORIN and ZETIA. Prescription Pharmaceuticals segment profit increased to $1.394 billion from $733 million, and gross margin improved to 65.1 percent. Cash flow from operating activities was $2.2 billion. The company is in the Build the Base phase of its Action Agenda. Key risks highlighted include the dependence of profits on the cholesterol franchise (which faced new generic entrants in December 2006), declining PEG-INTRON and REBETOL sales in Japan, the Consent Decree with the FDA, and several material government investigations. The company settled the Massachusetts Investigation for an aggregate $435 million in August 2006 and pleaded guilty through a subsidiary in January 2007, while AWP litigation, third-party payor actions and other matters remain pending. The filing states that the U.S. operations generated negative cash flow in 2006 and are expected to do so again in 2007. For 2007, the company does not provide numeric guidance but expects VYTORIN and ZETIA sales to grow, expects R&D expenses (excluding upfront payments) to grow faster than adjusted net sales, and anticipates approximately $100 million in annualized manufacturing cost savings. Total cash, cash equivalents and short-term investments less total debt was approximately $3.3 billion at year-end 2006.

    Feb 28, 2007
  23. 2005

    Merck Annual Report, Year Ended Dec 31, 2005

    Schering-Plough Corporation's 2005 10-K filing reveals a significant turnaround year, with net sales increasing by 15% to $9.5 billion, driven primarily by strong performance in the Prescription Pharmaceuticals segment. This growth was largely attributed to the success of the cholesterol franchise (VYTORIN and ZETIA), developed in partnership with Merck, which captured a notable share of the market. The company also saw a return to profitability, with net income available to common shareholders of $183 million, a substantial improvement from the prior year's net loss. This recovery was achieved despite ongoing litigation charges and the lingering effects of regulatory issues, including a Consent Decree with the FDA. Management highlighted progress in its 'Action Agenda' aimed at stabilizing and improving the company's performance, marking the beginning of a 'Turnaround' phase.

    Feb 28, 2006
  24. 2004-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 2004

    This is not Merck's annual report. The filing is Amendment No. 1 to Schering-Plough Corporation's Form 10-K for fiscal 2004 (filed under MRK-related context, but the registrant is Schering-Plough). It was filed to add audited combined financial statements for 2004 and unaudited combined financial statements for 2003 for the Merck/Schering-Plough Cholesterol Partnership, as required by Rule 3-09 of Regulation S-X. No other parts of the original 10-K are amended, so it does not contain Merck's or Schering-Plough's consolidated results, risk factors, or MD&A. The Partnership holds the joint commercialization rights to ezetimibe, marketed as ZETIA and EZETROL, and to its combination with simvastatin, marketed as VYTORIN and INEGY. Reported 2004 combined net sales were $1,214 million. The U.S. accounted for about 83% of 2004 sales, down from 88% in 2003. Partners' capital was a deficit of $66 million at December 31, 2004, after distributions of $855 million to the partners in 2004. The statements reflect only expenses contractually agreed to be shared, so they are not a complete picture of a standalone company's costs. Deloitte & Touche issued an unqualified opinion on the 2004 statements dated March 30, 2005. The 2003 figures are unaudited. For investors, the filing is most useful as a supplemental look at the economics of the ZETIA/VYTORIN collaboration. It shows high cash distributions relative to a small partners' deficit, substantial concentration of receivables (three customers held about 80% of year-end receivables), and reliance on the partners' infrastructure. It is not a standalone earnings or valuation document for either parent company.

    Mar 31, 2005
  25. 2004

    Merck Annual Report, Year Ended Dec 31, 2004

    Schering-Plough Corporation faced a challenging year in 2004, marked by a significant net loss of $947 million. This downturn was largely attributed to the loss of market exclusivity for key products like CLARITIN and REBETOL, coupled with increased market competition and substantial special charges related to litigation and restructuring. Despite a slight decrease in overall net sales to $8.3 billion, the company saw growth in specific segments like Animal Health and Consumer Health Care, and notable international sales increases for REMICADE. The company is actively pursuing a turnaround strategy under new leadership, focusing on key growth drivers such as the cholesterol franchise (VYTORIN and ZETIA) developed in partnership with Merck, and is seeking to improve financial stability through various means, including the repatriation of foreign earnings under the American Jobs Creation Act of 2004.

    Mar 9, 2005
  26. 2003-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 2003

    Merck & Co., Inc.'s 2003 Form 10-K, as amended on May 2, 2004, primarily serves to update Exhibit 10(u) concerning a Distribution Agreement with Centocor, Inc. dated April 3, 1998. This amendment does not alter the core financial statements or operational disclosures of the original filing, with the exception of certain omitted information from Exhibit 10(u) for which confidential treatment was requested. Investors should note that this filing is an amendment and not a restatement of the entire 2003 annual report.

    May 3, 2004
  27. 2003

    Merck Annual Report, Year Ended Dec 31, 2003

    Schering-Plough Corporation faced a challenging year in 2003, marked by a significant decline in net sales, primarily due to the loss of market exclusivity and subsequent generic competition for its leading product, CLARITIN. This led to a net loss for the year, a stark contrast to the profits reported in 2002 and 2001. The company is actively implementing a Value Enhancement Initiative (VEI) to cut costs, including workforce reductions and a substantial dividend cut, signaling a period of financial restructuring. Key drivers of the downturn include the conversion of CLARITIN to over-the-counter status, which drastically reduced its average selling price and exposed it to intense competition, and increased competition for its INTRON franchise in the hepatitis C market. Management is placing significant reliance on the joint venture with Merck & Co. for ZETIA and the ezetimibe/simvastatin combination to drive future growth. The company also faces ongoing legal and regulatory investigations, which have resulted in increased litigation reserves.

    Feb 26, 2004
  28. 2002

    Merck Annual Report, Year Ended Dec 31, 2002

    Schering-Plough Corporation's 2002 annual report shows consolidated net sales of $10.18 billion, up 4% from $9.76 billion in 2001, with price increases of 3% and favorable foreign exchange of 1%, while sales volume was unchanged. Net income was $1.97 billion, or $1.34 diluted earnings per share, compared with $1.94 billion and $1.32 in 2001. Results include a $150 million pre-tax provision to increase litigation reserves and an $80 million gain from the sale of U.S. marketing rights for SUBOXONE and SUBUTEX. Excluding the 2002 provision and the 2001 $500 million consent decree provision, the company states that diluted earnings per share declined 10% in 2002. The filing signals a sharp near-term earnings headwind from the U.S. switch of CLARITIN to over-the-counter status. U.S. CLARITIN prescription sales fell to $1.4 billion from $2.7 billion, and management believes the OTC switch, a competing OTC loratadine product, and additional generic entrants will have a rapid, sharp and material adverse effect on results for an indeterminate period. Growth was driven by the INTRON franchise (PEG-INTRON and REBETOL for hepatitis C), which reached $2.7 billion, up 89%, though management expects a competing pegylated interferon product to weaken its share. The company also faces substantial legal and regulatory exposure. It disclosed ongoing federal investigations into marketing practices, pharmacy benefit manager and managed care arrangements, and Medicaid rebate calculations, and it increased litigation reserves by $150 million in February 2003. Patent litigation over the desloratadine compound patent is on appeal, and a $195 million IRS claim has not been accrued. Liquidity remains sufficient, with cash and short-term investments of $4.0 billion against $1.4 billion of short-term borrowings, though management expects that cushion to shrink in 2003.

    Mar 10, 2003
  29. 2001

    Merck Annual Report, Year Ended Dec 31, 2001

    Schering-Plough Corporation reported net sales of $9,802 million for 2001, essentially flat versus $9,815 million in 2000, with volume declines of 2 percent and unfavorable foreign exchange of 2 percent offset by price increases of 4 percent. Net income fell 20 percent to $1,943 million, or $1.32 diluted earnings per share, after a one-time $500 million provision for a consent decree payment tied to FDA good manufacturing practice issues at its New Jersey and Puerto Rico plants. Excluding that provision, net income was $2.3 billion and diluted EPS was $1.58, down 4 percent. Cash provided by operating activities was $2,512 million. The filing's central investor concern is CLARITIN, which accounted for 28 percent of 2001 worldwide sales ($2.7 billion in U.S. sales). The company faces patent litigation against 15 generic manufacturers, with generic loratadine possibly entering the market as early as December 20, 2002, and it has filed sNDAs to switch CLARITIN to over-the-counter status with a targeted FDA action date of November 28, 2002. Management states that either generic or OTC entry would likely cause a rapid, sharp and material adverse effect on results of operations. Other pressures include a negotiated FDA consent decree, a grand jury investigation into managed care transactions, numerous average wholesale price lawsuits, and an IRS assertion of about $195 million in additional tax. Growth drivers in 2001 included the INTRON franchise (up 6 percent to $1.4 billion), anti-infectives and anticancer products (up 13 percent), NASONEX (up 26 percent) and REMICADE and TEMODAR. Cardiovascular sales fell 17 percent, reflecting generic competition for K-DUR and IMDUR. Research and development spending was $1,312 million, about 13 percent of net sales.

    Mar 29, 2002
  30. 2000

    Merck Annual Report, Year Ended Dec 31, 2000

    Schering-Plough Corporation, now Merck & Co., Inc., reported 2000 net sales of $9.8 billion, up 8 percent from $9.1 billion in 1999, with net income rising 15 percent to $2.4 billion ($2,423 million) and diluted earnings per share of $1.64. Growth was led by allergy and respiratory products, where CLARITIN sales reached $3.0 billion, and by anti-infective and anticancer products, where INTRON A/REBETRON Combination Therapy totaled $1.4 billion, up 21 percent. Income before income taxes was $3.2 billion, the effective tax rate fell to 24.0 percent, and cash provided by operating activities was $2.5 billion. The filing is dominated by risk disclosures. The FDA has cited current Good Manufacturing Practice deficiencies at the company's New Jersey and Puerto Rico facilities, and the company said that manufacturing process and control issues reduced U.S. sales of certain products, so first-quarter and full-year 2001 sales and earnings will be lower than expected. The FDA has said these deficiencies must be resolved before it approves the pending NDA for CLARINEX (desloratadine) Tablets. Following the February 2001 announcement, shareholder securities class actions were filed, and Standard & Poor's and Moody's revised their long-term debt outlooks to negative. The company also faces CLARITIN generic challenges, with loratadine's U.S. compound patent expiring in 2002, and numerous antitrust, investigation and product liability matters. The balance sheet remained solid, with cash of $2.4 billion and a debt-to-total-capital ratio of 15 percent, up from 12 percent in 1999. Shareholders' equity rose to $6.1 billion. Share repurchases totaled $855 million in 2000, and dividends paid were $802 million, or $0.545 per share. Cash and cash equivalents were $2,397 million at year-end.

    Mar 13, 2001
  31. 1999

    Merck Annual Report, Year Ended Dec 31, 1999

    Important discrepancy: the filing supplied is not from Merck & Co. (MRK). It is the 10-K for Schering-Plough Corporation (NYSE, Commission file 1-6571) for the fiscal year ended December 31, 1999. The analysis below covers Schering-Plough. Please confirm the intended filing before relying on it for Merck. Schering-Plough reported a strong 1999. Net sales rose 14% to $9.18 billion, driven by volume growth of 13%. Net income grew 20% to $2.11 billion, and diluted EPS rose 20% to $1.42. Growth was led by the allergy and respiratory franchise (CLARITIN, NASONEX, VANCENASE), which reached $3.85 billion in sales, and by the anti-infective and anticancer category (INTRON A and REBETRON for hepatitis C, plus TEMODAR), which grew 38% to $1.74 billion. Gross margin held near 80%, SG&A fell to 37.4% of sales from 38.9%, and R&D rose 18% to $1.19 billion (13.0% of sales). The effective tax rate was steady at 24.5%. The key investor risks are concentration and litigation. CLARITIN's U.S. compound patent expires in 2002, and generic filers (Geneva, Teva, Copley, Novex, Zenith Goldline, and Andrx for CLARITIN-D) are challenging it. The company also faces more than 110 antitrust actions, an ongoing FTC price-fixing investigation, a federal subpoena on disease management programs, an FDA Warning Letter on its New Jersey aerosol plants, and a Biogen royalty arbitration. Balance sheet strength is solid: cash of $1.88 billion, debt at 12% of total capital, and operating cash flow of $1.89 billion, which covered $716 million in dividends and $504 million in buybacks.

    Mar 2, 2000
  32. 1997

    Merck Annual Report, Year Ended Dec 31, 1997

    Important: the filing provided is Schering-Plough Corporation's Form 10-K for fiscal year 1997, not Merck & Co.'s (MRK) filing, so this analysis covers Schering-Plough (NYSE: SGP). Schering-Plough had a strong 1997. Sales rose 20% to $6.78 billion, driven mainly by volume growth of 20%, with worldwide CLARITIN sales reaching $1.7 billion (up from $1.2 billion). Income from continuing operations grew 19% to $1.44 billion, and diluted EPS rose 20% to $1.95. The company's 24.5% effective tax rate was unchanged, and the June 1997 purchase of Mallinckrodt's animal health business added about $171 million of 1997 sales. Management also cut the debt-to-total-capital ratio to 18% from 30%, while returning capital through a $542 million dividend and $132 million of share repurchases. The main investor questions center on concentration and litigation. CLARITIN is the dominant growth driver, and in February 1998 generic maker Geneva filed an ANDA seeking to market a generic Claritin several years before patent expiration. Schering-Plough sued in March 1998, and management believes it should prevail, but it gave no assurance of that. The company also faces more than 160 antitrust actions over prescription drug pricing, an FTC price-fixing investigation, a Foxmeyer-related suit seeking $400 million, and 185 lawsuits involving more than $2 billion in claimed damages tied to synthetic estrogens (DES). Management considers material liability beyond amounts accrued to be remote in most cases. Operating investments are rising. R&D spending reached $847 million, about 12.5% of sales, and SG&A rose to 39.3% of sales as the company expanded its field force and promotion. Capital expenditures were $373 million, with about $490 million planned for 1998. Year 2000 remediation is estimated at about $50 million, with completion expected by year-end 1998. Foreign sales were about 40% of the total, and no single foreign country exceeded 5% of consolidated sales.

    Mar 19, 1998
  33. 1996

    Merck Annual Report, Year Ended Dec 31, 1996

    Important correction first: the document provided is Schering-Plough Corporation's (NYSE: SGP) Form 10-K for fiscal year 1996, not Merck & Co. (MRK). The analysis below covers Schering-Plough. Its 1996 results were strong. Sales rose 11% to $5.66 billion, driven by 13% volume growth, with price down 1% and currency down 1%. Income from continuing operations grew 15% to $1.21 billion, and earnings per share from continuing operations rose 16% to $3.30. The company's pre-tax margin held near 28%, with an effective tax rate of 24.5%. Growth was concentrated in CLARITIN, whose worldwide sales reached $1.15 billion versus $789 million in 1995, along with INTRON A, IMDUR, and CEDAX. Offsetting this, PROVENTIL sales fell 25% to $316 million as generic metered-dose inhalers eroded the franchise. The company's OTC business declined 16%. The balance sheet strengthened, with shareholders' equity rising to $2.06 billion from $1.62 billion and the debt-to-total-capital ratio falling to 30% from 36%. Operating cash flow was $1.46 billion, against capital expenditures of $325 million, $388 million of share repurchases, and $474 million of dividends. The quarterly dividend was increased 14% to $0.33 during 1996. Cash and equivalents ended the year at $535 million, and the company reported $1.3 billion in unused credit lines. R&D spending reached $723 million, about 12.8% of sales. Investors should note the litigation exposure. The company faces 149 lawsuits over synthetic estrogen (DES) with more than $2 billion claimed, more than 160 antitrust actions by pharmacies and consumers, a $400 million suit from the FoxMeyer bankruptcy estate, and an FTC price-fixing investigation. Management considers material losses beyond accruals remote, but these matters are a key risk. Also note that a $63.6 million THEO-DUR product liability judgment is under appeal.

    Mar 3, 1997
  34. 1995-A3

    Merck Annual Report (Amendment), Year Ended Dec 31, 1995

    The document provided is not a Merck & Co. (MRK) 10-K filed June 26, 1996. It is Amendment No. 1 to Schering-Plough Corporation's Form 10-K for fiscal year 1995, dated June 14, 1996. Its only purpose is to attach the Form 11-K annual report for the Schering-Plough Employees' Savings Plan (Exhibit 28(b)). It contains no operating results, revenue, earnings, pipeline, or balance sheet data for either company, so it cannot support an investment analysis of Merck or of Schering-Plough as an operating business. The analysis below covers only the savings plan's financial statements. Investors looking for Merck's 1995 annual results should obtain Merck's own 10-K. At December 31, 1995, the savings plan held net assets available for benefits of $179.9 million, up from $133.7 million a year earlier, an increase of $46.3 million (about 35%). Total additions were $58.7 million, made up of $40.8 million of investment income (including $29.9 million of net appreciation) and $17.9 million of participant contributions. Benefit payments were $12.4 million. Schering-Plough common stock, held through the Schering-Plough Stock Fund, was the largest single holding at $57.8 million, versus $36.9 million in 1994. Vanguard registered investment company shares totaled $116.5 million. The plan had 9,437 participants and beneficiaries at year end. The filing has internal inconsistencies. The narrative in Exhibit II describes the plan's net assets as of December 31, 1994 and an increase of $16,336,749, with total income of $22,055,393. These figures do not match the audited statements, which show a 1995 increase of $46,277 thousand and year-end 1995 net assets of $179,927 thousand. The audited statements should be treated as authoritative, and the narrative appears to be carried over from an earlier year's report.

    Jun 26, 1996
  35. 1995-A2

    Merck Annual Report (Amendment), Year Ended Dec 31, 1995

    The document you provided is not a Merck & Co. (MRK) 10-K annual report. It is Amendment No. 2 to Schering-Plough Corporation's Form 10-K for the fiscal year ended December 31, 1995, filed June 24-25, 1996. Its sole purpose is to add the Form 11-K annual report for The Schering-Plough Puerto Rico Employees' Retirement Savings Plan, which Schering-Plough filed as Exhibit 28(b). The filing contains no information on Merck's business, revenues, earnings, or strategy, so it cannot support an investment analysis of MRK. The plan is a defined contribution savings plan covering Puerto Rico employees of Schering-Plough Products, Inc. and Schering-Plough del Caribe, Inc. Net assets available for benefits rose 31% to $7,332,952 at December 31, 1995, from $5,587,441 a year earlier. Participants fell from 1,032 to 836, and the increase came mainly from $996,722 of net investment appreciation and $1,372,202 of participant contributions. Roughly 84% of plan assets were in Vanguard registered investment company shares, with the Vanguard Index 500 Portfolio the largest holding at $3.03 million. Schering-Plough stock held in the plan was valued at $245,165, or $247.68 per unit. The independent auditor, Deloitte & Touche LLP (San Juan), issued an unqualified opinion on the plan's financial statements. The main investor-relevant item is that the 1995 sale of Schering-Plough's vision care division led to a $711,687 transfer of participant accounts to a successor savings plan. For a Merck analysis, you would need Merck's own 10-K for fiscal 1995 or 1996, which this document does not include.

    Jun 25, 1996
  36. 1995-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 1995

    The filing excerpt provided does not support the requested analysis. It is labeled as Form 10-K/A, Amendment No. 1, and names Schering-Plough Corporation as the registrant, not Merck & Co., Inc. (MRK) as the request states. The excerpt contains only the SEC cover-page header and no financial statements, business description, risk factors, MD&A, or other substantive content, so no financial performance, revenue, earnings, pipeline, or balance-sheet conclusions can be drawn from it. Before any investor-facing analysis is prepared, the correct filing should be retrieved from EDGAR, confirming the registrant name, CIK, form type, and filing date (June 14, 1996). If the intended company is Merck, its own 10-K for the relevant fiscal year should be used. If the Schering-Plough amendment is the intended document, the full text, including the amended sections, should be supplied so the analysis can be completed.

    Jun 14, 1996
  37. 1995

    Merck Annual Report, Year Ended Dec 31, 1995

    Important note: the filing provided is Schering-Plough Corporation's (not Merck & Co.'s) Form 10-K for fiscal 1995, filed February 28, 1996. The analysis below is based on the Schering-Plough document. Schering-Plough had a strong 1995. Sales rose 13% to $5.10 billion, driven mainly by CLARITIN (worldwide sales of $789 million, up from $505 million) and the respiratory franchise, which grew 29% domestically. Income from continuing operations rose 14% to $1.05 billion, and EPS from continuing operations was $2.85, up 18%, helped by share repurchases. Reported net income was $886.6 million ($2.40 per share), reduced by a $156.2 million after-tax loss on the June 1995 sale of the contact lens business, which was treated as a discontinued operation. The main risks are product concentration and generic competition. PROVENTIL (albuterol) sales of $422 million are expected to decline as a generic metered-dose inhaler was approved in December 1995 and Warrick Pharmaceuticals launched its own version. THEO-DUR also faced generic pressure, and INTRON A sales in Japan fell to $94 million from $141 million, as Japanese health authorities worked to control costs. Litigation exposure is significant but management considers material loss remote: more than 150 antitrust suits by pharmacies and consumers (a $22.1 million federal class settlement is pending court approval), more than 95 estrogen-related product liability suits claiming over $2 billion, and a $63.6 million THEO-DUR judgment under appeal. Financially, the company is in solid shape. Operating cash flow was $1.38 billion, capital expenditures were $293.8 million, and the company repurchased 9.9 million shares for $493.8 million. The dividend rose to $1.125 per share from $0.99, and the debt-to-capital ratio fell to 36% from 38%. Debt is modest, with total long-term debt of $87.1 million and short-term borrowings of $841.3 million, and the company held A-1+/P-1 commercial paper ratings and AA/Aa3 bond ratings. R&D spending was $656.9 million, or 12.9% of sales.

    Feb 28, 1996
  38. 1994-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 1994

    Important note: this document is not a Merck & Co. (MRK) 10-K. It is Amendment No. 1 to Schering-Plough Corporation's Form 10-K for fiscal 1994, filed June 26, 1995. Its only substance is a Form 11-K annual report for the Schering-Plough Employees' Savings Plan, a defined contribution plan. It contains no Merck or Schering-Plough corporate financial statements, revenue, earnings, or segment data, so it offers little direct insight into company performance or valuation. Within the plan, net assets available for benefits rose 13.9% to $133.65 million at December 31, 1994, from $117.31 million a year earlier. The net increase of $16.34 million came from $16.97 million in participant and other contributions and $5.08 million in investment income, partly offset by $1.95 million in net depreciation in investment value and $5.72 million in benefits paid. Participants grew to about 9,400 from 8,900. The Schering-Plough Stock Fund, valued at $36.9 million, rose 14.3% and its unit value increased to $167.62 from $155.37. The plan's largest holding was the Vanguard Windsor Fund ($38.4 million), and the Vanguard U.S. Treasury money market portfolio nearly doubled to $27.4 million, suggesting a shift toward cash-like safety. For investors, the filing's main value is as a signal of employee sentiment and retirement-asset allocation. Employee holdings of company stock grew alongside the stock's unit value, and the plan is open to all domestic employees with a one-year service requirement. Plan administration costs are borne by the company. Investors seeking Merck financial information should consult Merck's own annual report for fiscal 1994.

    Jun 26, 1995
  39. 1994

    Merck Annual Report, Year Ended Dec 31, 1994

    Important note: the document provided is Schering-Plough Corporation's (NYSE: SGP) Form 10-K for fiscal year 1994, not Merck & Co. (MRK). The analysis below is based on the Schering-Plough filing. Schering-Plough reported 1994 sales of $4,657.1 million, up 7% from $4,341.3 million in 1993. Volume grew 5% and price increases contributed 2%. Growth was driven mainly by CLARITIN, the nonsedating antihistamine, with worldwide sales of $505 million. Net income rose 12% to $922.0 million excluding the 1993 accounting change, and earnings per share were $4.82, up 14% on the same basis. The effective tax rate was 24.0%. Return on average shareholders' equity was 58.4%, reflecting a small equity base after share repurchases. The main headwinds were Japan and generic competition. Sales of INTRON A in Japan fell to $141 million from $307 million after a government-mandated price cut and cost-containment measures. Generic competition for PROVENTIL and THEO-DUR is expected to weigh on respiratory sales, and PROVENTIL alone generated $396 million in 1994. Research and development spending rose 7% to $620.0 million, or 13.3% of sales, and the company says the Puerto Rico tax exemption phase-down will add about 2 percentage points to the effective tax rate starting in 1996. The balance sheet strengthened. Short-term borrowings fell to $782.3 million from $1,076.0 million, and the ratio of debt to total capital declined to 38% from 44%. The company repurchased 8.6 million shares for $599.4 million and raised the quarterly dividend to $.51 from $.45, bringing the annual dividend to $1.98. Key legal risks include a $63.6 million THEO-DUR product liability judgment under appeal, more than 95 synthetic estrogen (DES-related) suits claiming over $2 billion, and more than 100 pharmacy antitrust actions. Management considers the probability of material losses beyond amounts accrued to be remote. The company is also still deciding the future of its Wesley-Jessen vision care business, which has received more than $150 million in investment.

    Mar 3, 1995
  40. 1993-A

    Merck Annual Report (Amendment), Year Ended Dec 31, 1993

    This filing is not a Merck & Co. (MRK) 10-K. It is Amendment No. 1 to Schering-Plough Corporation's Form 10-K for fiscal 1993, which adds the Form 11-K annual report for the Schering-Plough Employees' Savings Plan. Merck is not mentioned in the document. The analysis below covers the content actually provided, and it is of limited relevance to MRK investors. It describes an employee benefit plan, not the company's operating or financial performance. The plan's net assets available for benefits rose 25.5% during 1993, from $93.5 million to $117.3 million. The increase was driven by $15.6 million in participant contributions and $11.6 million in investment earnings, offset by $3.3 million in distributions. Approximately 8,870 employees participated at year-end 1993, up from 8,407 a year earlier. Participants could allocate contributions across eight investment funds. The Schering-Plough common stock fund, valued at $32.3 million, was the largest single holding at roughly 28% of plan assets. Its net asset value per unit increased from $144.49 to $155.37, about 7.5%. The Vanguard investment portfolios held $80.2 million, and participant loans totaled $4.8 million. The plan's unallocated insurance contract matured on December 31, 1993, at an interest rate of about 8.23%, and its funds were moved into Vanguard funds or the company stock fund. Deloitte & Touche issued an unqualified opinion dated June 7, 1994.

    Jun 16, 1994
  41. 1993

    Merck Annual Report, Year Ended Dec 31, 1993

    Important note: the filing provided is Schering-Plough Corporation's (not Merck & Co.'s) Form 10-K for fiscal year 1993, covering its pharmaceutical and health care products business. The analysis below is based on that document. Please verify the company and ticker before using it for investment decisions. Schering-Plough reported 1993 sales of $4,341.3 million, up 7% from $4,055.7 million, driven mainly by CLARITIN, the once-daily antihistamine launched in the U.S. in 1993 (worldwide sales of $295 million), and INTRON A, the alpha interferon, which exceeded $570 million. Income before the extraordinary item and accounting changes rose 15% to $825.0 million, and EPS before those items was $4.23, up 18%, helped by share repurchases. Reported net income was $730.8 million ($3.75 per share), held down by a one-time $94.2 million after-tax charge for adopting SFAS No. 106 (postretirement benefits). The effective tax rate fell to 23.5%. The main risks are PROVENTIL, whose U.S. sales fell 17% to $353 million as generic competition grew and may increase after generic albuterol inhalers are approved in 1994; the expected 1994 decline in INTRON A sales in Japan due to a government-mandated price cut; increasing U.S. and international pricing pressure, including proposed health care reform; and the phase-down of Puerto Rico tax exemptions under the 1993 Omnibus Budget Reconciliation Act. Litigation includes DES-related suits claiming about $750 million in total and about sixty antitrust suits, which management does not expect to be material. Net debt rose to $824.3 million, and the company spent $418.3 million on share repurchases and $339.6 million on dividends.

    Mar 7, 1994